Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to learn what effects (good and bad) bevacizumab in conjunction with carboplatin/paclitaxel and radiation therapy has on patients with non-small cell lung cancer (NSCLC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Brigham and Women's Hospital; Massachusetts General Hospital
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Histologically confirmed non-small cell lung cancer (NSCLC) that have been evaluated and determined not to be candidates for surgical resection as part of their definitive management of stage III disease.

• Age 18 years or older

• ECOG performance status of 0-1

• Life Expectancy of greater than six months

• Normal organ and marrow function

• Women and men of child-bearing potential must agree to use adequate contraception

Exclusion Criteria:

• Prior chemotherapy or thoracic radiation therapy

• Squamous histology or any histology in close proximity to a major vessel

• Active hemoptysis

• History of hypercoagulability

• Known distant metastatic disease

• History of allergic reactions attributed to compounds with similar chemical or biological composition to bevacizumab, carboplatin, paclitaxel or other agents used in this study

• Patients with uncontrolled intercurrent illness

• Pregnant women

• Major surgical procedure, open biopsy, or significant traumatic injury with in 28 days prior to day 0

• Minor surgical procedure within 7 days to day 0

• HIV-positive patients receiving combination anti-retroviral therapy.

• Non-skin cancer malignancy in the past 5 years.